Carrie Bhang is a research investigator in In Vivo Pharmacology at Novartis Oncology and is particularly interested in applying what we have learned
about tumor heterogeneity to drug discovery and the development of combination therapies.
These details tell researchers
about the
heterogeneity of
tumors, which is essential for developing appropriate research and drug protocols that can navigate all the inherent complexity of not just the anatomy and physiology being imaged but also how imaging technologies intersect to capture as much information as possible.